c-FLIP, a master anti-apoptotic regulator
dc.contributor.author | Safa, A. R. | |
dc.contributor.department | Department of Pharmacology and Toxicology, IU School of Medicine | en_US |
dc.date.accessioned | 2016-09-07T18:05:49Z | |
dc.date.available | 2016-09-07T18:05:49Z | |
dc.date.issued | 2012-10 | |
dc.description.abstract | Cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) is a master anti-apoptotic regulator and resistance factor that suppresses tumor necrosis factor-α (TNF-α), Fas-L, and TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, as well as apoptosis triggered by chemotherapy agents in malignant cells. c-FLIP is expressed as long (c-FLIP(L)), short (c-FLIP(S)), and c-FLIP(R) splice variants in human cells. c-FLIP binds to FADD and/or caspase-8 or -10 and TRAIL receptor 5 (DR5) in a ligand-dependent and -independent fashion and forms an apoptosis inhibitory complex (AIC). This interaction in turn prevents death-inducing signaling complex (DISC) formation and subsequent activation of the caspase cascade. c-FLIP(L) and c-FLIP(S) are also known to have multifunctional roles in various signaling pathways, as well as activating and/or upregulating several cytoprotective and pro-survival signaling proteins including Akt, ERK, and NF-kB. Upregulation of c-FLIP has been found in various tumor types, and its silencing has been shown to restore apoptosis triggered by cytokines and various chemotherapeutic agents. Hence, c-FLIP is an important target for cancer therapy. For example, small interfering RNAs (siRNAs) that specifically knockdown the expression of c-FLIP(L) in diverse human cancer cell lines augmented TRAIL-induced DISC recruitment and increased the efficacy of chemotherapeutic agents, thereby enhancing effector caspase stimulation and apoptosis. Moreover, small molecules causing degradation of c-FLIP as well as decreasing mRNA and protein levels of c-FLIP(L) and c-FLIP(S) splice variants have been found, and much effort is focused on developing other c-FLIP-targeted cancer therapies. This review focuses on (1) the anti-apoptotic role of c-FLIP splice variants in preventing apoptosis and inducing cytokine and chemotherapy drug resistance, (2) the molecular mechanisms and factors that regulate c-FLIP expression, and (3) modulation of c-FLIP expression and function to eliminate cancer cells or increase the efficacy of anticancer agents. This article is part of a Special Issue entitled "Apoptosis: Four Decades Later". | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Safa, A. R. (2012). c-FLIP, A MASTER ANTI-APOPTOTIC REGULATOR. Experimental Oncology, 34(3), 176–184. | en_US |
dc.identifier.issn | 1812-9269 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/10873 | |
dc.language.iso | en_US | en_US |
dc.publisher | Morion | en_US |
dc.relation.journal | Experimental Oncology | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Apoptosis | en_US |
dc.subject | CASP8 and FADD-Like Apoptosis Regulating Protein | en_US |
dc.subject | metabolism | en_US |
dc.subject | Neoplasms | en_US |
dc.subject | drug therapy | en_US |
dc.subject | Signal Transduction | en_US |
dc.title | c-FLIP, a master anti-apoptotic regulator | en_US |
dc.type | Article | en_US |